<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958696</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0018318-104</org_study_id>
    <secondary_id>2016-003313-99</secondary_id>
    <secondary_id>16-024</secondary_id>
    <nct_id>NCT02958696</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules</brief_title>
  <official_title>A Phase 1, Randomised, Open Label, 2-period Crossover, Single Centre, 3-arm, Single Dose Study to Investigate the Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsule Formation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HTL0018318 is a selective muscarinc M1 agonist. This study is a phase I, open label,&#xD;
      randomised, crossover, single dose, trial in healthy volunteers to compare the relative&#xD;
      bioavailability of HTL0018318 when given by oral aqueous solution and in capsule formulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of HTL0018318</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Comparison of bioavailability in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) of HTL0018318</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Comparison of bioavailability in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (tmax)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CLp/F)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted in urine (Ae)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction excreted in urine (fe/F)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance in urine (CLr)</measure>
    <time_frame>Predose to 168h post dose</time_frame>
    <description>Pharmacokinetics in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>Predose up to 28 days post dose</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Predose up to 28 days post dose</time_frame>
    <description>Heart rate and blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>Predose up to 28 days post dose</time_frame>
    <description>Physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety assessments</measure>
    <time_frame>Predose up to 28 days post dose</time_frame>
    <description>Hematology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>Predose up to 28 days post dose</time_frame>
    <description>ECG</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Bioavailability and Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>HTL0018318 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose aqueous solution and/or equivalent low dose capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0018318 mid dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mid dose aqueous solution and/or equivalent mid dose capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0018318 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose aqueous solution and/or equivalent high dose capsule(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0018318</intervention_name>
    <description>Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.</description>
    <arm_group_label>HTL0018318 high dose</arm_group_label>
    <arm_group_label>HTL0018318 low dose</arm_group_label>
    <arm_group_label>HTL0018318 mid dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female healthy volunteer.&#xD;
&#xD;
          2. Aged 18-55 years.&#xD;
&#xD;
          3. A body mass index (Quetelet index) in the range 18.0-34.&#xD;
&#xD;
          4. Sufficient intelligence to understand the nature of the trial and any hazards of&#xD;
             participating in it. Ability to communicate satisfactorily with the investigator and&#xD;
             to participate in, and comply with the requirements of, the entire trial.&#xD;
&#xD;
          5. Willingness to comply with the contraception requirements of the trial.&#xD;
&#xD;
          6. Willingness to give written consent to participate after reading the information and&#xD;
             consent form, and after having the opportunity to discuss the trial with the&#xD;
             investigator or his delegate.&#xD;
&#xD;
          7. Willingness to give written consent to have data entered into The Overvolunteering&#xD;
             Prevention System.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at&#xD;
             the pre-trial screening assessment that could interfere with the objectives of the&#xD;
             trial or the safety of the volunteer.&#xD;
&#xD;
          2. QTcF outside range 300-450 msec for males, and 300-470 msec for females at resting ECG&#xD;
             at screening and baseline.&#xD;
&#xD;
          3. Family history of unexplained sudden death, or sudden death due to long QT syndrome.&#xD;
&#xD;
          4. Clinically relevant abnormal findings based on 24 h ECG Holter monitoring during&#xD;
             screening, including any of the following: &gt; 200 ventricular ectopic heart beats,&#xD;
             ventricular tachycardia, defined as &gt;= 3 successive ventricular ectopic beats at a&#xD;
             rate of &gt;120 bpm, second degree heart block, sustained cardiac arrhythmias, including&#xD;
             atrial fibrillation, complete heart block and supraventricular tachycardia (SVT), any&#xD;
             symptomatic arrhythmia except isolated extra systoles.&#xD;
&#xD;
          5. Aspartate transaminase (AST), alanine transaminase (ALT), gamma glutamyl transferase&#xD;
             (GGT) or total bilirubin &gt;1.5 x ULN at screening, or other laboratory blood chemistry&#xD;
             test results outside the normal reference range unless deemed not clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
          6. Clinically significant renal insufficiency as indicated by a glomerular filtration&#xD;
             rate lower than the age-related L at screening. In the event of a glomerular&#xD;
             filtration rate &gt;80, eligibility may be confirmed by a second measurement.&#xD;
&#xD;
          7. Blood pressure and heart rate in supine position at the screening examination outside&#xD;
             the ranges 90-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45-100 beats/min.&#xD;
             Subject with borderline values can be included if the values are deemed not clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
          8. Presence of acute or chronic illness or history of chronic illness sufficient to&#xD;
             invalidate the volunteer's participation in the trial or make it unnecessarily&#xD;
             hazardous.&#xD;
&#xD;
          9. Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory,&#xD;
             haematological, renal or neurological function, diabetes mellitus, coronary heart&#xD;
             disease, or history of any psychotic mental illness deemed clinically significant by&#xD;
             the investigator.&#xD;
&#xD;
         10. History of a chronic respiratory condition, such as asthma, recurrent chest infections&#xD;
             of chronic obstructive pulmonary disease.&#xD;
&#xD;
         11. History of epilepsy or seizures.&#xD;
&#xD;
         12. History of a severe allergy. Non-active hayfever is acceptable.&#xD;
&#xD;
         13. Surgery (e.g. stomach bypass) or medical condition that might affect absorption,&#xD;
             metabolism or elimination of medicines.&#xD;
&#xD;
         14. Presence or history of severe adverse reaction to any drug.&#xD;
&#xD;
         15. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and&#xD;
             not using a reliable method of contraception.&#xD;
&#xD;
         16. Use of a prescription or over-the-counter medicine, or any herbal remedy or&#xD;
             nutritional supplement, during the 21 days before the first dose of trial medication&#xD;
             until the end of the study, with the exception of acetaminophen (paracetamol),&#xD;
             hormonal contraceptives or hormone replacement therapy (HRT).&#xD;
&#xD;
         17. Presence or history of drug or alcohol abuse in the last 5 years, or intake of more&#xD;
             than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women),&#xD;
             or use of cigarettes or nicotine-containing products during the 3 months before the&#xD;
             first dose until the end of the study.&#xD;
&#xD;
         18. Evidence of drug abuse on urine testing.&#xD;
&#xD;
         19. Positive test for hepatitis B, hepatitis C or HIV.&#xD;
&#xD;
         20. Positive test for alcohol or smoking before dosing.&#xD;
&#xD;
         21. Participation in another clinical trial of a new chemical entity or a prescription&#xD;
             medicine within the previous 3 months.&#xD;
&#xD;
         22. Loss of more than 500 mL blood during the 3 months before the trial, eg as a blood&#xD;
             donor.&#xD;
&#xD;
         23. Possibility that the volunteer will not cooperate with the requirements of the&#xD;
             protocol.&#xD;
&#xD;
         24. Objection by General Practitioner (GP) to volunteer entering trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adeep Puri, MPhil MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

